We continue to hear from Pradaxa patients who experienced frightening episodes of bleeding while using this blood thinner. Considering that there is no readily available antidote for Pradaxa bleeding, we are not surprised by the ISMP’s findings.
New York, NY (PRWEB) January 19, 2013
Pradaxa side effects continue to be reported to the U.S. Food & Drug Administration (FDA), Bernstein Liebhard LLP reports. According to the latest QuarterWatch Report issued by the Institute for Safe Medicine Practices (ISMP), an analysis of hemorrhage cases reported to the FDA during the second quarter of 2012 found that Pradaxa bleeding is 5 times more likely to result in death compared to warfarin bleeding. The estimate of higher odds for a fatal outcome persisted after adjusting for differences in patient age, gender, and report source, the ISMP said.*
“We continue to hear from Pradaxa patients who experienced frightening episodes of bleeding while using this blood thinner. Considering that there is no readily available antidote for Pradaxa bleeding, we are not surprised by the ISMP’s findings,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The firm is currently offering free Pradaxa lawsuit evaluations to individuals who suffered life-threatening hemorrhaging, allegedly due to Pradaxa.
Pradaxa, which is used to prevent strokes in people with a heart-rhythm disorder known as atrial fibrillation, was approved by the U.S. Food & Drug Administration (FDA) in October 2010. According to a recent report from Bloomberg.com, regulators in several countries have issued Pradaxa safety alerts since the drug was first brought to market.** Most recently, the FDA released a Drug Safety Communication announcing a new contraindication was being added to the Pradaxa label to warn against its use in patients with mechanical heart valves.***
At least 176 Pradaxa lawsuits have been consolidated in a multidistrict litigation now underway in U.S. District Court, Southern District of Illinois. The complaints allege plaintiffs suffered serious, life-threatening episodes of Pradaxa bleeding, and that Boehringer Ingelheim sold the blood thinner despite knowing it could cause fatal bleeding in some patients. According to court documents, the Pradaxa litigation’s first trial has been scheduled for August 2014. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
Victims of serious Pradaxa bleeding may be eligible to collect compensation for their medical bills, lost wages, pain and suffering and more. To learn more, please visit the firm’s Pradaxa lawsuit website, or call 1-877-779-1414 to speak with an attorney today.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com